11.17 (-0.58%)
As of Jan 03, 2023
Source:
Oyster Point Pharma, Inc. (the Company) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases. The Company's lead product candidate OC-01 (varenicline) nasal spray, a highly selective nicotinic acetylcholine receptor (nAChR) agonist, is being developed as a nasal spray to treat the signs and symptoms of dry eye disease.
Country | United States |
Headquarters | princeton, new jersey |
Phone Number | (609) 382-9032 |
Industry | manufacturing |
CEO | |
Website |